NCT06842472 2025-02-24
PD-L1 Inhibitor + RT ± Ursodeoxycholic Acid in Recurrent/Metastatic HER2-Neg Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
Clinical Trials
3 trialsNCT06733233 2024-12-13
A Study Evaluating the Efficacy and Safety of De Trastuzumab (T-DXd) in Combination with Immunotherapy for the Neoadjuvant Treatment of HR-positive HER2 Low-expressing Chinese Patients with Early-stage Breast Cancer
Guangzhou Women and Children's Medical Center
Phase 2 Not yet recruiting
NCT06547476 2024-08-09
Chidamide and PD-1 Inhibitor Plus Anlotinib for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed
Guangdong Provincial People's Hospital
Phase 2 Not yet recruiting